In patients with stage IV melanoma receiving PD-1 (pembrolizumab) therapy, the magnitude of reinvigoration of circulating Tex cells, determined in relation to the pre-treatment tumor burden, correlated with the clinical response (24). This evidence concerns the gene PDCD1 and melanoma.